Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

740P - Response assessment in advanced renal cell carcinoma (mRCC) patients (pts) treated by Nivolumab (N) + Ipilimumab (I): CT volumetric measurement versus RECIST 1.1 response criteria

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Renal Cell Cancer

Presenters

Quentin Minault

Citation

Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274

Authors

Q. Minault1, P. Barthélémy2, P. Leyendecker1, M. mielcarek3, C. roy1

Author affiliations

  • 1 Radiologie B, Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, 67091 - Strasbourg/FR
  • 2 Department Of Medical Oncology, Les Hôpitaux Universitaires de Strasbourg/ Institut de Cancérologie Strasbourg Europe, 67000 - Strasbourg/FR
  • 3 Biostatistiques, Hôpitaux Universitaires de Strasbourg, 67000 - Strasbourg/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 740P

Background

N+I improved Overall survival and overall response rate in intermediate/poor-risk pts with a clear cell aRCC. However, 20 % of pts didn’t respond to immunotherapy. Identification of early progression is crucial to initiate rapidly a new therapy. We aimed to compare two radiological volumetric methods versus RECIST 1.1 gold standard unidimensional measurement in clear cell aRCC treated by N+I.

Methods

Forteen pts with clear cell aRCC treated with N+I were included in a retrospective monocentric non-interventional study. Follow-up CT scan explorations were reviewed by two blinded- radiologists. Unidimensional RECIST and volumetric measurements were compared at each time-point. The main criteria was the inter-observer agreement for each method. The secondary criteria was the tumoral response assessment based on three different items: RECIST 1.1, spherical volumetric method (SVM), ellipsoidal volumetric method (EVM). Last criteria was median time to progression in each tumoral response assessment.

Results

Forteen aRCC pts were identified (median age 63.6). Intraclass coefficient correlation in volumetric method (0.986 [95% CI: 0.980, 0.990]) was higher than in RECIST (0.903 [95% CI: 0.861, 0.928]). Relative measurement differences with Bland and Altman plot was lower in volumetric method with shorter limits of agreement (0.8%; upper LOA95%: 36.5; lower LOA95%: −35), versus those in RECIST (-5.1 % (upper LOA95%: 46; lower LOA95%: −57). Volumetric method (especially ellipsoidal one) assesses progression disease earlier than RECIST for 57% (N= 8) pts. Median time to progression was 17 months, 18 months and 22 months, respectively with SVM, EVM and RECIST. No difference for partial response assessment was identified.

Conclusions

Volumetric assessment for tumoral response in metastatic RCC may predict earlier the progression disease with a higher inter-observer agreement.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.